|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.|
|US8158616||ELI LILLY AND CO||Azetidine and cyclobutane derivatives as JAK inhibitors|| |
(6 years from now)
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8420629||ELI LILLY AND CO||Azetidine and cyclobutane derivatives as JAK inhibitors|| |
(5 years from now)
|US9737469||ELI LILLY AND CO||Methods for treating hair loss disorders|| |
(7 years from now)
|US9089574||ELI LILLY AND CO||Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections|| |
(9 years from now)
|US11045474||ELI LILLY AND CO||Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections|| |
(9 years from now)
Olumiant is owned by Eli Lilly And Co.
Olumiant contains Baricitinib.
Olumiant has a total of 5 drug patents out of which 0 drug patents have expired.
Olumiant was authorised for market use on 31 May, 2018.
Olumiant is available in tablet;oral dosage forms.
Olumiant can be used as treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo), treatment of adult patients with severe alopecia areata, treatment of rheumatoid arthritis.
Drug patent challenges can be filed against Olumiant from 2022-05-31.
The generics of Olumiant are possible to be released after 30 November, 2032.
|Drug Exclusivity||Drug Exclusivity Expiration|
|New Chemical Entity Exclusivity (NCE)||May 31, 2023|
|New Indication (I)||May 10, 2025|
NCE-1 date: 2022-05-31
Market Authorisation Date: 31 May, 2018
Treatment: Treatment of rheumatoid arthritis; Treatment of adult patients with severe alopecia areata; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-i...